search
Back to results

Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
UPLIFT
Usual care
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Coping, Relaxing

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of hypertension based on the criteria in the ICD-9/-10
  • Mild to moderate depressive symptoms (PHQ-9 ≥ 5)
  • English-speaking
  • If taking depression medications, medications must stable for the past 6 weeks (no change to type or dose)
  • Willing to provide informed consent, be audio-recorded, and comply with all other aspects of protocol

Exclusion Criteria:

  • Moderate to severe depressive symptoms (PHQ-9 ≥ 15)
  • Current substance abuse
  • Current eating disorder
  • Self-harm within the past 3 months
  • Current obsessive-compulsive disorder
  • Current anxiety disorder (e.g., PTSD, panic disorder)
  • Active suicidal ideation
  • History of or current diagnosis of psychosis
  • Significant cognitive impairment (mini mental state examination score ≤ 20)
  • History of previous training in mindfulness
  • History of more than 8 sessions of cognitive behavioral therapy
  • Counseling more frequently than once per month

Sites / Locations

  • New York University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

UPLIFT

Usual Care

Arm Description

Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.

Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.

Outcomes

Primary Outcome Measures

Feasibility measured by the number of weekly sessions attended
Determined by the number of weekly sessions attended and number of days of home-based practice completed each week
Acceptability
8-item Client Satisfaction Questionnaire (CSQ-8)
PHQ-9
validated measure of depressive symptoms. Items rate symptom severity during the prior 2 weeks based on DSM-IV diagnostic criteria for major depression. Scores range from 0-27; scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-9 will be completed at screening and at all study visits (continuous scores).
Quick Inventory of Depressive Symptomatology (QIDS-SR 16)
Standardized depression instrument that has treatment sensitivity advantages over the PHQ-9 and will be administered at pre- and post-treatment. Total scores on the QIDS-SR16 range from 0 to 27 and reflect depression severity across 9 domains of the DSM-IV MDD criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.

Secondary Outcome Measures

Full Information

First Posted
January 5, 2017
Last Updated
November 12, 2019
Sponsor
NYU Langone Health
search

1. Study Identification

Unique Protocol Identification Number
NCT03013907
Brief Title
Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study
Official Title
Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
October 12, 2018 (Actual)
Study Completion Date
October 12, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to adapt and then evaluate the feasibility, acceptability, and efficacy of a telephone-based intervention (UPLIFT: Using Practice and Learning to Increase Favorable Thoughts) for individuals with elevated depressive symptoms and hypertension. UPLIFT is a group-based intervention that is delivered over 8 weekly sessions for 1 hour/week by phone. Aim 1 of this study is to adapt UPLIFT using qualitative focus groups and individual interviews and to test the adapted UPLIFT program in a single-arm design. Aim 2 of this study is a randomized controlled trial (RCT) that will compare the effects of the adapted UPLIFT program to usual care (UC) and to test mediators and moderators of the effects of UPLIFT.
Detailed Description
Once 16 participants are enrolled (to form 2 groups of 8 patients each), an independent study staff member will determine participants' group assignments. The randomization sequence will be created a priori by Dr. Keith Goldfeld (biostatistician) by using a computer-generated list of random numbers with stratification by antidepressant medication use and baseline levels of depressive symptoms (PHQ scores <10 and ≥10). UPLIFT: Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment. Usual care: Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Coping, Relaxing

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
UPLIFT
Arm Type
Experimental
Arm Description
Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
Arm Title
Usual Care
Arm Type
Active Comparator
Arm Description
Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
Intervention Type
Behavioral
Intervention Name(s)
UPLIFT
Intervention Description
Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
Intervention Type
Behavioral
Intervention Name(s)
Usual care
Intervention Description
Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
Primary Outcome Measure Information:
Title
Feasibility measured by the number of weekly sessions attended
Description
Determined by the number of weekly sessions attended and number of days of home-based practice completed each week
Time Frame
6 Months
Title
Acceptability
Description
8-item Client Satisfaction Questionnaire (CSQ-8)
Time Frame
6 Months
Title
PHQ-9
Description
validated measure of depressive symptoms. Items rate symptom severity during the prior 2 weeks based on DSM-IV diagnostic criteria for major depression. Scores range from 0-27; scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-9 will be completed at screening and at all study visits (continuous scores).
Time Frame
6 Months
Title
Quick Inventory of Depressive Symptomatology (QIDS-SR 16)
Description
Standardized depression instrument that has treatment sensitivity advantages over the PHQ-9 and will be administered at pre- and post-treatment. Total scores on the QIDS-SR16 range from 0 to 27 and reflect depression severity across 9 domains of the DSM-IV MDD criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes.
Time Frame
6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of hypertension based on the criteria in the ICD-9/-10 Mild to moderate depressive symptoms (PHQ-9 ≥ 5) English-speaking If taking depression medications, medications must stable for the past 6 weeks (no change to type or dose) Willing to provide informed consent, be audio-recorded, and comply with all other aspects of protocol Exclusion Criteria: Moderate to severe depressive symptoms (PHQ-9 ≥ 15) Current substance abuse Current eating disorder Self-harm within the past 3 months Current obsessive-compulsive disorder Current anxiety disorder (e.g., PTSD, panic disorder) Active suicidal ideation History of or current diagnosis of psychosis Significant cognitive impairment (mini mental state examination score ≤ 20) History of previous training in mindfulness History of more than 8 sessions of cognitive behavioral therapy Counseling more frequently than once per month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amanda Shallcross, MD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study

We'll reach out to this number within 24 hrs